Department of Neurology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Centre for Child Health, Hangzhou, 310052, China.
Pharmacy Department, Bupa Cromwell Hospital, Kensington, London, SW5 0TU, UK.
J Transl Med. 2023 May 27;21(1):351. doi: 10.1186/s12967-023-04220-5.
The current ageing trend of the world population has, in part, accounted for Alzheimer disease (AD) being a public health issue in recent times. Although some progress has been made in clarifying AD-related pathophysiological mechanisms, effective intervention is still elusive. Biometals are indispensable to normal physiological functions of the human body-for example, neurogenesis and metabolism. However, their association with AD remains highly controversial. Copper (Cu) and zinc (Zn) are biometals that have been investigated at great length in relation to neurodegeneration, whereas less attention has been afforded to other trace biometals, such as molybdenum (Mo), and iodine. Given the above context, we reviewed the limited number of studies that have evidenced various effects following the usage of these two biometals in different investigative models of AD. Revisiting these biometals via thorough investigations, along with their biological mechanisms may present a solid foundation for not only the development of effective interventions, but also as diagnostic agents for AD.
目前，世界人口的老龄化趋势在一定程度上导致阿尔茨海默病（AD）成为近年来的一个公共卫生问题。尽管在阐明 AD 相关病理生理机制方面已经取得了一些进展，但仍然难以进行有效的干预。生物金属对于人体的正常生理功能是不可或缺的，例如神经发生和代谢。然而，它们与 AD 的关联仍然存在很大争议。铜（Cu）和锌（Zn）是与神经退行性变相关的生物金属，已经进行了大量研究，而其他痕量生物金属，如钼（Mo）和碘，关注较少。鉴于上述情况，我们回顾了为数不多的研究，这些研究证明了在 AD 的不同研究模型中使用这两种生物金属后会产生各种影响。通过彻底的研究重新审视这些生物金属及其生物学机制，不仅可为开发有效的干预措施奠定坚实的基础，还可为 AD 的诊断试剂提供依据。
